BioAge Labs, Inc. (BIOA) stock
BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.10−0.12 (-2.30%)
Close on Nov 17, 2026Market cap $234.07MP/E –Yield –
BioAge Labs r&d expenses
Research and development expenses are spending on new products and technology.
BioAge Labs's R&D Expenses for the twelve months ending Jun 30, 2026 was $87.79M, up 25.1% year over year. For fiscal 2025 it was $73.97M, up 25.3% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.97M | +25.3% |
| FY2024 | Dec 31, 2024 | $59.04M | +74.2% |
| FY2023 | Dec 31, 2023 | $33.89M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $24.37M | +22.8% |
| Q1 FY2026 | Mar 31, 2026 | $20.41M | +83.7% |
| Q4 FY2025 | Dec 31, 2025 | $24.50M | +27.4% |
| Q3 FY2025 | Sep 30, 2025 | $18.51M | -7.5% |
| Q2 FY2025 | Jun 30, 2025 | $19.84M | +89.5% |
| Q1 FY2025 | Mar 31, 2025 | $11.11M | +19.2% |
| Q4 FY2024 | Dec 31, 2024 | $19.23M | +90.7% |
| Q3 FY2024 | Sep 30, 2024 | $20.02M | +206.5% |
| Q2 FY2024 | Jun 30, 2024 | $10.47M | – |
| Q1 FY2024 | Mar 31, 2024 | $9.32M | – |
| Q4 FY2023 | Dec 31, 2023 | $10.08M | – |
| Q3 FY2023 | Sep 30, 2023 | $6.53M | – |
See a number that looks wrong?